NIH unit grants XOMA $65M to work on botulism treatment

09/10/2008 | American City Business Journals

The National Institute of Allergy and Infectious Diseases awarded XOMA a $65 million contract to develop a treatment for botulism, a potentially lethal disease caused by a neurotoxin from the bacterium Clostridium botulinum. XOMA intends to begin trials next year for its first antibody product against the disease.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI